What sector is GENB in?

Generate Biomedicines, Inc. is classified under GICS Health Care (Biotechnology).

What is GENB's last close price?

GENB last closed at $13.66 on 2026-07-16.

GENB

NASDAQNext earnings·Aug 6

Generate Biomedicines, Inc.

Health Care · Biotechnology

$13.66last close

+8.0%~252d

Price

+2.17% over 1M

Thesis

as of 2026-07-16

Clinical-stage generative-biology platform - AI-designed protein therapeutics. 3M net), Phase 3 SOLAIRIA-1/2 testing GB-0895 anti-TSLP in severe asthma. $516M cash post-IPO with ~$80M/qtr burn; runway into 1H 2028. 2M quarterly milestone revenue - most platform value remains back-end-loaded.

•2022 - Amgen collaboration signed: up to $1.9B value, 5 initial + 5 optional protein-therapeutic programs
•Pre-IPO - Novartis collaboration signed: >$1B potential value, AI-designed protein therapeutics
•2026-02-26 - NASDAQ IPO priced: 25M shares at $16 = $400M gross ($369.3M net proceeds)
•2026-02-27 - Day 1 close $12.65 (-21% from IPO price); $300M of proceeds earmarked for GB-0895 Phase 3 completion
•2026-Q1 - Reported $7.2M revenue (vs $8.8M Y/Y), net loss $61.7M (vs $44.3M Y/Y), R&D $57.8M (vs $46.8M Y/Y), operating cash burn $80.4M
•2026-mid - GB-4362 (MMAE neutralizer, FDA Fast Track granted) expected first-patient dosing; oncology indication
•2026-2H - GB-5267 (MUC16 CAR-T) expected first-patient dosing in Phase 1 solid-tumor trial (ovarian initially); Roswell Park Comprehensive Cancer Center partnership
•Snapshot 2026-05-18: price ~$13.01, mcap ~$1.67B (128.2M sh), cash $516.6M, runway into 1H 2028 per company guidance
•Setup tension: ~6.5 quarters of runway vs Phase 3 SOLAIRIA readout dates undisclosed - fundraise risk likely before next major data milestone; Amgen + Novartis partnerships generate only $7.2M/qtr today, most value is milestone-dependent and back-end-loaded; IPO ran $16 → $16.82 → $13, full give-back of the post-IPO pop

Analyze GENB· interactive tools

Conviction· in 1 watchlist

Top correlated· 252d co-movement

0.40
0.38
0.35
0.34
0.33

Frequently asked questions

What sector is GENB in?: Generate Biomedicines, Inc. is classified under GICS Health Care (Biotechnology).
What is GENB's last close price?: GENB last closed at $13.66 on 2026-07-16.